Czech Republic - Czech - SUKL (Státní ústav pro kontrolu léčiv)

stada arzneimittel ag, bad vilbel array - 510 difenhydramin-hydrochlorid - gel - 10mg/g - difenhydramin

Czech Republic - Czech - SUKL (Státní ústav pro kontrolu léčiv)

medochemie ltd., limassol array - 363 cinarizin; 498 dimenhydrinÁt - tableta - 20mg/40mg - cinarizin, kombinace

European Union - Czech - EMA (European Medicines Agency)

qbiotics netherlands b.v. - tigilanol tiglate - tigilanol tiglate - psi - pro léčbu non-resekabilním, non-metastatický (kdo staging) podkožní mastocytů se nachází na nebo distální k lokti, nebo hleznu, a non-resekabilním, non metastazující kožní žírných buněk nádory u psů.

Czech Republic - Czech - SUKL (Státní ústav pro kontrolu léčiv)

janssen-cilag s.r.o., praha array - 4991 domperidon - potahovaná tableta - 10mg - domperidon

Czech Republic - Czech - USKVBL (Ústav Pro Státní Kontrolu Veterinárních Biopreparátů A Léčiv)

zoetis Česká republika s.r.o. (2) - karprofen - injekční roztok - deriváty kyseliny propionové - kočky, psi

European Union - Czech - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastická činidla - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

European Union - Czech - EMA (European Medicines Agency)

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - lymfom, mantle-cell - antineoplastická činidla - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).

European Union - Czech - EMA (European Medicines Agency)

roche registration gmbh - mosunetuzumab - lymfom, folikulární - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.

European Union - Czech - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - mnohočetný myelom - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

European Union - Czech - EMA (European Medicines Agency)

roche registration gmbh  - glofitamab - lymphoma, large b-cell, diffuse - antineoplastická činidla - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.